Flash if you’ve questions and concerns about our CEO/SAB/BOD/Ariana’s ability to design and conduct a sufficiently powered ph2/3 Alzheimer’s Disease trial, then I’d suggest you contact the Company directly and posit your recommendations to those that have control over the process.
I doubt that anyone on this message board will be able to influence their trial design/implementation.
Frankly either the Anavex compounds “work” or they don’t. Isn’t that what will largely determine success or failure here?
Have you been digesting all of the Anavex clinical and preclinical results over the past 1-2 years across the CNS disease spectrum? Along with the numerous quotes and articles/abstracts and independent studies and results and presentations from outside experts (Dr Francardo, Dr Perry, Dr Lisak, Journal of the Alzheimer’s Association on 12/29/17, among others), along with the over 100 prior peer reviewed studies regarding the positive benefits of Sigma-1 receptor agonists?
Do you dispute the science, or just Anavex’s abilities to implement trials and funding?
Our MOA isn’t only targeting the AD indication. Please check out the Company pipeline again.
These are CNS diseases and maladies with SIGNIFICANT UNMET NEEDS. The current SOC drugs have a very low (efficacy) bar to clear, and many have dreadful side effects; patients deserve better.
Our compound has been shown to be safe and with tangential health & quality of life benefits (reduction of oxidative stress, restoration of cellular homeostasis, insomnia relief, improved mood/coordination, reduced anxiety) per the Company’s prior representations and presentations stemming from their research and from our phase 2/2a trial participants and their caregivers (see below).
No I’m not a scientist and I’m only reporting my understanding of the current situation, but with what above do you disagree?
Excerpted from Jefferies slide from June 2017:
"PATIENT EVENTS: THERAPEUTIC RESPONSE UNEXPECTED
101001 MORE ALERT REGARDING SURROUNDINGS
101002 FEELS MUCH HAPPIER MAKING JOKES
101003 MUCH HAPPIER WHEN ATTENDING CLINIC APPTS AND ENJOYS MAKING JOKES
AND ENGAGES WELL IN CONVERSATION
101004 BETTER HAND COORDINATION. CALMER AND MORE COMMUNICATIVE
101006 IMPROVING MOODS. READING MORE BOOKS
101007
ABILITY TO PLAY THE PIANO AND READ MUSIC NOTES AT ABOUT 9 MONTHS
INTO TRIAL. SHE USED TO PLAY THE PIANO AT AGE 5 AND LOST HER ABILITY PREALZHEIMER
TRIAL
101010 ABLE TO FOLLOW PLOT WHEN WATCHING MOVIES WHEREAS PREVIOUSLY
COULD NOT
101010 MORE COMPASSION FOR CHILDREN
101011 WIFE THINKS PATIENT IS A BIT MORE CHEERFUL
101013 ABLE TO DO MUCH MORE HOUSEWORK THAN BEFORE
101013 MORE DRIVEN AND UPBEAT LESS ANXIOUS ACCORDING TO CARER
101014
AN INTERNATIONAL ARTIST WHO RESUMED HER PAINTING ABILITIES AND NOW HAVING AN EXHIBITION IN NOV 2016. WRITTEN A 3 PAGE LETTER TO LONG LOST
BROTHER
101015 PLAYING MORE GOLF NOW BY HIMSELF. MORE CONFIDENT AT GOING OUT BY
HIMSELF
101017 ENJOYED HER TRIP TO BELGIUM - TALKS ABOUT SOME BITS OF HER TRIP
102001 IMPROVED ENGAGEMENT WITH FAMILY/FRIENDS/OUTSIDE WORLD
102008 IMPROVEMENT IN MOOD
102010 FEELING GREAT - IMPROVEMENT IN COGNITION AND MOOD, BALANCE AND
GAIT HAS IMPROVED
103001 PATIENT REMEMBERING SOMETHING HE WOULDN'T HAVE PREVIOUSLY"
